Evidence Hub

11-Oxygenated Androgens in Pcos: Impact of Pcos Phenotypes and First-Line Interventions

Dokras A, Kunselman AR, Stetter CM, McPhaul M, Stanczyk FZ, Legro RS

The Journal of clinical endocrinology and metabolism, 2026

1 citation

Abstract

CONTEXT

Androgen excess in polycystic ovary syndrome (PCOS)/polyendocrine metabolic ovarian syndrome (PMOS) is classically attributed to ovarian steroids, yet adrenal-derived 11-oxygenated androgens are potent contributors whose regulation and treatment responsiveness in PMOS remains poorly characterized.

OBJECTIVE

To quantify classic and 11-oxygenated androgens across PMOS phenotypes versus controls and to evaluate their responses to oral contraceptive pills (OCPs), metformin, or lifestyle modification (LSM).

DESIGN

Secondary analysis of residual serum samples from three trials: OWL-PCOS (16-week OCP vs LSM), COMET-PCOS (24-week OCP vs metformin), and AMIGOS (controls).

SETTING

Two academic medical centers.

PATIENTS OR OTHER PARTICIPANTS

276 with Rotterdam-defined PMOS and 97 controls.

INTERVENTION(S)

Low dose OCPs (4-6 months), metformin (2000mg/day for 6 months), or LSM (4 months).

MAIN OUTCOME MEASURE(S)

Serum concentrations of 11β-hydroxytestosterone (11-OHT), 11-ketotestosterone (11-KT), 11-ketoandrostenedione (11-KA4), and 11β-hydroxyandrostenedione (11-OHA4) measured by LC-MS/MS, and total testosterone (TT), at baseline and end of study.

RESULTS

Adjusting for age and BMI, women with PCOS/PMOS had higher median 11-OHT (11.0 vs 7.8 ng/dL; P = 0.01) and 11-KT (31.9 vs 25.6 ng/dL; P = 0.03) than controls. Elevations were phenotype-specific: biochemical hyperandrogenism showed broad increases, whereas clinical hyperandrogenism with normal TT found no significant…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free